Yes Nxydias, they have called it really well. They upped their recommendation recently (from sell to hold) when the share price touched the low $1.70's, so I believe anyone following their call (NOT their content or analysis behind the call) would be pretty happy with the results thus far. BUT, to not give the company a +ve rerating post receiving a greenlight from the FDA for this OA study, seems out of place... Time will tell, but so far they have been correct (Collins ST Cap, also sold stock in the mid $3's as well) on their calls. I am taking the other side as are all shareholders....
Cheers
Tanami
research reports and media, page-2176
-
- There are more pages in this discussion • 2,180 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.015(6.52%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 25.0¢ | 23.0¢ | $76.82K | 326.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18490 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 34357 | 3 |
View Market Depth
| Last trade - 11.54am 06/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |